Pioglitazone, etoricoxib, interferon-a, and metronomic capecitabine for metastatic renal cell carcinoma: Final results of a prospective phase II trial

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 799-805

  Walter, B ^e   Schrettenbrunner, I ^a   Vogelhuber, M ^a   Grassinger, J ^a   Bross, K ^a   Wilke, J ^b   Suedhoff, T ^c   Berand, A ^a   Wieland, W F ^a   Rogenhofer, S ^d   Andreesen, R ^a   Reichle, A ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Hospital of Fuerth   (Germany)

^c Department of Haematology and Oncology   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Anti inflammatory agents; C reactive protein; Metastatic renal cell carcinoma; Metronomic chemotherapy; Tumor microenvironment

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CAPECITABINE; ETORICOXIB; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ANTIVIRUS AGENT; CYCLOOXYGENASE 2 INHIBITOR; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PYRIDINE DERIVATIVE; SULFONE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; KIDNEY METASTASIS; LOW DRUG DOSE; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; CANCER STAGING; CLINICAL TRIAL; FEMALE; FOLLOW UP; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2 INHIBITORS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDINES; SULFONES; SURVIVAL RATE; THIAZOLIDINEDIONES;

EID: 84866303137     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9982-0     Document Type: Article

References (26)

1. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436-44. doi:10.1038/nature07205.
2. Solinas G, Marchesi F, Garlanda C, et al. Inflammation-mediated promotion of invasion, metastasis. Cancer Metastasis Rev. 2010; 29(2):243-8.
3. Motzer RJ, Molina AM. Targeting renal cell carcinoma. J Clin Oncol. 2009;10:3274-6. doi:10.1200/JCO.2009.21.8461.
4. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144-50. doi:10.1200/JCO.2009.26.7849.
5. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561.
6. Bellmunt J, Trigo JM, Calvo E. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010;11(4):350-7. doi:10.1016/S1470-2045(09)70383-3.
7. Reichle A, Vogt T. Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron. 2008;1:159-70. doi: 10.1007/s12307-008-0012-5.
8. Reichle A, Grassinger J, Bross K, et al. C-reactive protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation. Biomarker Insights. 2007;1:87-98.
9. Gehan EA, Tefft MC. Will there be resistance to the RECIST (response evaluation criteria in solid tumors) J. Natl Cancer Inst. 2000;92:179-81. doi:10.1093/jnci/92.3.179.
10. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25(29):4542-9. doi:10.1200/JCO.2007.11.2136.
11. Shinohara N, Kumagai A, Kanagawa K, et al. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2009;39(11):720-6. doi:10.1093/jjco/hyp089.
12. Rini BI, Weinberg V, Dunlap S, et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer. 2006;106(3): 566-75. doi:10.1002/cncr.21661.
13. Tilg H, Vogel W, Dinarello CA. Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood. 1995;85:433-5.
14. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003;9(1):1-9.
15. Panigrahy D, Huang S, Kieran MW, et al. PPAR-gamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther. 2005;4:687-93.
16. Hafner C, Reichle A, Vogt T. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARc agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Current Cancer Drug Targets. 2005; 5(6):393-419.
17. Hazra S, Peebles KA, Sharma S et al. The role of PPARc in the cyclooxygenase pathway in lung cancer. PPAR Res 2008 doi: 10.1155/2008/790568.
18. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2(12):733-40. doi:10.1016/S1470-2045 (01)00587-3.
19. Sunela KL, Koskinen S, Kellokumpu-Lehtinen P. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer. Cancer Chemother Pharmacol. 2010;66(1):59-67. doi:10.1007/s00280-009-1134-2.
20. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer. 1997;33:1794-8. doi:10.1016/S0959-8049(97)00179-2.
21. Bromwich E, McMillan DC, Lamb GW, et al. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer. 2004;91:1236-8. doi:10.1038/sj.bjc. 6602152.
22. Saito K, Tatokoro M, Fujii Y, et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol. 2009;55:1145-53. doi:10.1016/j.eururo.2008. 10.012.
23. Johnson TV, Abbas A, Owen-Smith A, et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell carcinoma. J Urol. 2010;193:480-5.
24. Limura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009;181:1004-12.
25. Kedar I, Mermershtain W, Ivgi H, et al. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2- based therapy. Int J Cancer. 2004;110:260-5. doi: 10.1002/ijc.20089.
26. Kerr C. Inflammatory response predicts survival in renal cancer. Lancet Oncol. 2006;7:284. doi:10.1016/S1470-2045(06)70632-5.